Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 6/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1387709 | 0.77 | TRPV4 (0.39) | TRPV4ARPGR | |
| SCHEMBL29212775 | 0.69 | KDM4E (0.38) | TRPV4ARPGR | |
| SCHEMBL6651902 | 0.65 | TRPV4 (0.48) | TRPV4UPP1AR | |
| SCHEMBL7959821 | 0.65 | UPP1 (0.46) | TRPV4UPP1ARESR2CA12 | |
| SCHEMBL29416744 | 0.64 | ESR1 (0.44) | TRPV4UPP1ARESR2PGR | |
| SCHEMBL14920227 | 0.64 | TRPV4 (0.43) | TRPV4UPP1ARESR2ESR1 | |
| SCHEMBL17110582 | 0.64 | TRPV4 (0.45) | TRPV4ARPGR | |
| SCHEMBL1128771 | 0.64 | ESR1 (0.44) | TRPV4UPP1ARESR2PGR | |
| SCHEMBL349000 | 0.62 | — | — | |
| SCHEMBL176946 | 0.62 | TRPV4 (0.57) | TRPV4ARESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1195166-B1 | Use of a vasopressin antagonist such as conivaptan in the manufacture of a medicament for treating pulmonary hypertension | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-6740648-B2 | USING A VASOPRESSIN ANTAGONIST SUCH AS CONIVAPTAN | WARNER-LAMBERT COMPANY | 2004-05-25 | — | — | US | disclosed |
| US-20020128259-A1 | Treatment of pulmonary hypertension | ASTELLAS IRELAND CO., LTD. (IE) | 2002-09-12 | — | — | US | disclosed |
| EP-1195166-A2 | Use of a vasopressin antagonist such as conivaptan in the manufacture of a medicament for treating pulmonary hypertension | WARNER-LAMBERT COMPANY (US) | 2002-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128259-A1 | Treatment of pulmonary hypertension | AVPR2, AVPR1B, NPPA | TRPV4 1612/4885UPP1 1516/4885AR 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.